FDA slaps clin­i­cal hold on an­tibi­otics tri­al af­ter deaths in mon­key tri­al spurred con­cerns

5 years ago
FDA+

Re­gen­eron has a win­ner in Dupix­ent and big sales hopes. So why are so few pa­tients tak­ing it?

5 years ago
Pharma

How will the Biden ad­min­is­tra­tion af­fect fund­ing for life sci­ence re­search?

5 years ago
Biotech Voices

Sanofi flunks Parkin­son's Phase II, ax­es hand­ful of mid-stage pro­grams in Q4 earn­ings

5 years ago
Pharma

PTC whiffs on an­oth­er Duchenne study, plans to go to FDA again any­way

5 years ago
R&D
FDA+

Covid-19 roundup: UK and Cure­Vac join forces to fight emerg­ing vari­ants; Sanofi and Glax­o­SmithK­line post snap­shot of ...

5 years ago
Coronavirus

As­traZeneca's Imfinzi fails main OS end­point in PhI­II for head and neck can­cer — and adding treme­li­mum­ab didn’t ...

5 years ago
R&D

FDA cites litany of er­rors at Lon­za Hous­ton plant at the cen­ter of Bris­tol My­ers CVR de­ba­cle

5 years ago
FDA+
Manufacturing

Rapid CD­MO growth marks a start to End­points Man­u­fac­tur­ing's first re­port — here's what to ex­pect from our cov­er­age

5 years ago
Manufacturing

'Gene ther­a­py is at an in­flec­tion point': Kathy High on her new perch at AskBio and the field­'s fu­ture

5 years ago
People

Ra­mona Se­queira to be­come PhRMA's first fe­male chair; McK­in­sey reach­es near­ly $574 mil­lion set­tle­ment over ...

5 years ago
News Briefing

Richard Bran­son takes 23andMe pub­lic with his SPAC, as the Glax­o­SmithK­line part­ner aims to beef up drug R&D

5 years ago
Financing

Shift to dig­i­tal leaves hun­dreds of Am­gen sales jobs on chop­ping block

5 years ago
Pharma

Roche chops TNBC pro­grams fol­low­ing PhI­II flops, fur­ther dim­ming the spot­light on Ar­ray drug

5 years ago
R&D

Mer­ck CEO Ken Fra­zier pre­pares to step down af­ter 29 years, hand­ing the keys to the Keytru­da race car to CFO Robert ...

5 years ago
People

Sana prices at near record IPO, lead­ing pack of Nas­daq new­com­ers

5 years ago
Financing

Weighed down by safe­ty con­cerns of JAK port­fo­lio, Pfiz­er hatch­es a deal to go a dif­fer­ent di­rec­tion in rheuma­toid ...

5 years ago
Deals

Mer­ck KGaA goes toe to toe with No­var­tis as FDA green-lights MET in­hibitor

5 years ago
Pharma
FDA+

Se­nior Ab­b­Vie li­ai­son quits job to launch neu­ro start­up, with sights set on ALS

5 years ago
Financing

Prothena re­vives its for­mer lead drug, aim­ing for a small­er pop­u­la­tion with more se­vere cas­es

5 years ago
FDA+

Re­call re­port: Apo­tex re­calls 2 batch­es of blood-thin­ner in­jec­tion af­ter sy­ringe mis­la­bel­ing sna­fu

5 years ago
FDA+
Manufacturing

Year-end earn­ings show tur­bu­lent times for Hal Bar­ron's Glax­o­SmithK­line turn­around

5 years ago
Pharma

Mu­ta­bilis re­ceives CARB-X grant for 'night­mare bac­te­ri­a' treat­ment; Ab­Sci and Xyphos shake hands on dis­cov­ery deal

5 years ago
News Briefing

In­novent and Lil­ly win sec­ond Chi­na OK for Tyvyt in front­line NSCLC, ramp­ing up pres­sure on king Keytru­da

5 years ago
China
FDA+
First page Previous page 747748749750751752753 Next page Last page
A service from the Financial Times